

# Louis S Matza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/657675/publications.pdf>

Version: 2024-02-01

55  
papers

1,460  
citations

394421

19  
h-index

345221

36  
g-index

55  
all docs

55  
docs citations

55  
times ranked

1945  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Pediatric Patient-Reported Outcome Instruments for Research to Support Medical Product Labeling: Report of the ISPOR PRO Good Research Practices for the Assessment of Children and Adolescents Task Force. <i>Value in Health</i> , 2013, 16, 461-479. | 0.3 | 322       |
| 2  | The Link Between Health-Related Quality of Life and Clinical Symptoms Among Children with Attention-Deficit Hyperactivity Disorder. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2004, 25, 166-174.                                      | 1.1 | 104       |
| 3  | Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. <i>European Journal of Health Economics</i> , 2011, 12, 219-230.  | 2.8 | 103       |
| 4  | Utilities and disutilities for type 2 diabetes treatment-related attributes. <i>Quality of Life Research</i> , 2007, 16, 1251-1265.   | 3.1 | 102       |
| 5  | Validation of two generic patient-reported outcome measures in patients with type 2 diabetes. <i>Health and Quality of Life Outcomes</i> , 2007, 5, 47.   | 2.4 | 56        |
| 6  | Preference for pharmaceutical formulation and treatment process attributes. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 1385-1399.   | 1.8 | 56        |
| 7  | Health State Utilities for Childhood Attention-Deficit/Hyperactivity Disorder Based on Parent Preferences in the United Kingdom. <i>Medical Decision Making</i> , 2005, 25, 56-70.  | 2.4 | 52        |
| 8  | Acute and chronic impact of cardiovascular events on health state utilities. <i>BMC Health Services Research</i> , 2015, 15, 173.   | 2.2 | 47        |
| 9  | Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations. <i>Value in Health</i> , 2021, 24, 812-821.  | 0.3 | 39        |
| 10 | Health state utilities associated with attributes of treatments for hepatitis C. <i>European Journal of Health Economics</i> , 2015, 16, 1005-1018.   | 2.8 | 35        |
| 11 | Assessing patient PREFERENCE between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 355-364.  | 4.4 | 31        |
| 12 | Health State Utilities Associated with Glucose Monitoring Devices. <i>Value in Health</i> , 2017, 20, 507-511.  | 0.3 | 28        |
| 13 | Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 90.                                  | 2.4 | 27        |
| 14 | Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. <i>Patient Preference and Adherence</i> , 2013, 7, 855.   | 1.8 | 23        |
| 15 | Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. <i>BMC Health Services Research</i> , 2017, 17, 774.  | 2.2 | 23        |
| 16 | Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2018, 34, 1457-1464.   | 1.9 | 22        |
| 17 | Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. <i>Current Medical Research and Opinion</i> , 2007, 23, 2051-2062.  | 1.9 | 21        |
| 18 | Health state utilities for skeletal-related events secondary to bone metastases. <i>European Journal of Health Economics</i> , 2014, 15, 7-18.  | 2.8 | 21        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | A qualitative examination of the content validity of the EQ-5D-5L in patients with type 2 diabetes. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 192.  | 2.4 | 20        |
| 20 | Physician perceptions of GLP-1 receptor agonists in the UK. <i>Current Medical Research and Opinion</i> , 2016, 32, 857-864.   | 1.9 | 20        |
| 21 | Development and validation of a patient-report measure of fatigue associated with depression. <i>Journal of Affective Disorders</i> , 2011, 134, 294-303.  | 4.1 | 19        |
| 22 | Impact of caregiver and parenting status on time trade-off and standard gamble utility scores for health state descriptions. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 48.                                | 2.4 | 18        |
| 23 | Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy. <i>Journal of Medical Economics</i> , 2019, 22, 806-813.    | 2.1 | 18        |
| 24 | The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation. <i>European Journal of Health Economics</i> , 2016, 17, 979-990.            | 2.8 | 17        |
| 25 | Health state utilities associated with post-surgical <i>Staphylococcus aureus</i> infections. <i>European Journal of Health Economics</i> , 2019, 20, 819-827.   | 2.8 | 15        |
| 26 | Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences. <i>Quality of Life Research</i> , 2019, 28, 2359-2372.                        | 3.1 | 15        |
| 27 | Multiple sclerosis relapse: Qualitative findings from clinician and patient interviews. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 139-146.   | 2.0 | 15        |
| 28 | A systematic literature review of cardiovascular event utilities. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 767-790.   | 1.4 | 14        |
| 29 | Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 971-979.      | 1.8 | 13        |
| 30 | The Fatigue Associated with Depression Questionnaire (FAsD): responsiveness and responder definition. <i>Quality of Life Research</i> , 2013, 22, 351-360.   | 3.1 | 12        |
| 31 | Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ). <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 43.             | 1.9 | 10        |
| 32 | Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK. <i>Drugs in R and D</i> , 2019, 19, 213-225.   | 2.2 | 10        |
| 33 | Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments. <i>Diabetes Therapy</i> , 2021, 12, 2387-2403.   | 2.5 | 10        |
| 34 | Health state utilities associated with treatment for transfusion-dependent $\beta^2$ -thalassemia. <i>European Journal of Health Economics</i> , 2020, 21, 397-407.  | 2.8 | 9         |
| 35 | Qualitative Research on Fatigue Associated with Depression: Content Validity of the Fatigue Associated with Depression Questionnaire (FAsD-V2). <i>Patient</i> , 2015, 8, 433-443.                                     | 2.7 | 8         |
| 36 | Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ). <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 44. | 1.9 | 8         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | &lt;p&gt;Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia&lt;/p&gt;. Patient Preference and Adherence, 2020, Volume 14, 2231-2242.                        | 1.8 | 8         |
| 38 | Health state utilities associated with adult attention-deficit/hyperactivity disorder. Patient Preference and Adherence, 2014, 8, 997.   | 1.8 | 7         |
| 39 | Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation. Quality of Life Research, 2017, 26, 1785-1798.      | 3.1 | 7         |
| 40 | Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI). Journal of Medical Economics, 2019, 22, 936-944.   | 2.1 | 7         |
| 41 | Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. Quality of Life Research, 2021, 30, 2033-2043.   | 3.1 | 7         |
| 42 | Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes. Patient, 2022, 15, 367-377.   | 2.7 | 7         |
| 43 | Challenges of Developing an Observable Parent-Reported Measure: A Qualitative Study of Functional Impact of ADHD in Children. Value in Health, 2017, 20, 828-833.  | 0.3 | 6         |
| 44 | Health state utilities associated with treatment options for acute myeloid leukemia (AML). Journal of Medical Economics, 2019, 22, 567-576.  | 2.1 | 6         |
| 45 | Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment among People Living with HIV. Patient, 2020, 13, 409-422.                               | 2.7 | 6         |
| 46 | A Review of Interventional Trials in Youth-Onset Type 2 Diabetes: Challenges and Opportunities. Diabetes Therapy, 2021, 12, 2827-2856.   | 2.5 | 6         |
| 47 | Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma. PharmacoEconomics - Open, 2022, 6, 367-376.   | 1.8 | 6         |
| 48 | A Scoring Algorithm for Deriving Utility Values from the Neuro-QoL for Patients with Multiple Sclerosis. Medical Decision Making, 2020, 40, 897-911.   | 2.4 | 5         |
| 49 | Development of a brief clinician-reported outcome measure of multiple sclerosis signs and symptoms: The Clinician Rating of Multiple Sclerosis (CRoMS). Multiple Sclerosis and Related Disorders, 2019, 35, 253-261.     | 2.0 | 4         |
| 50 | Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy. Diabetes Therapy, 2020, 11, 319-330.   | 2.5 | 4         |
| 51 | Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS). Journal of Medical Economics, 2020, 23, 978-984.  | 2.1 | 4         |
| 52 | Patientsâ€™ preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 367.e7-367.e17. | 1.6 | 4         |
| 53 | Health state utilities associated with weight loss in type 2 diabetes and obesity. Journal of Medical Economics, 2022, 25, 14-25.  | 2.1 | 3         |
| 54 | Cover Image, Volume 22, Issue 3. Diabetes, Obesity and Metabolism, 2020, 22, .   | 4.4 | 0         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ). Journal of Patient-Reported Outcomes, 2020, 4, 104. | 1.9 | 0         |